Previous 10 | Next 10 |
Compugen (NASDAQ: CGEN) stock didn't begin this week in a healthy way. The clinical-stage drug company's shares fell by just over 7% following a price target cut from an analyst tracking the company. Prognosticator Mark Breidenbach of Oppenheimer has trimmed said target by j...
Image source: The Motley Fool. Compugen Ltd (NASDAQ: CGEN) Q3 2021 Earnings Call Nov 12, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Compugen Ltd (CGEN) Q3 2021 Earnings Call Transcript
Compugen Ltd. (CGEN) Q3 2021 Earnings Conference Call November 12, 2021, 8:30 AM ET Company Participants Anat Cohen-Dayag – President and CEO Yvonne Naughton – Head of Investor Relations and Corporate Communications Henry Adewoye – Chief Medical Officer Ari Krashin ȁ...
Compugen (NASDAQ:CGEN) shares are trading ~4.0% lower in the pre-market after the company disclosed preliminary data from an ongoing Phase 1 dose-escalation study designed to test its anti-TIGIT antibody COM902 in patients with advanced solid tumors. The 18 patients enrolled in...
Compugen (NASDAQ:CGEN): Q3 GAAP EPS of -$0.07 beats by $0.05. Revenue of $6M Shares +4.47% PM. Press Release As of September 30, 2021, cash, cash related accounts, short-term and long-term bank deposits totaled approximately $102 million compared with approximately $124 million on December 31...
Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021 - Data presented further support Compugen's earlier findings that PVRIG plays a distinct role within the DNAM axis,...
Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Anti-TIGIT Antibody) at SITC 2021 - Dose escalation study clears the path to a comprehensive evaluation of Compugen's DNAM axis hypothesis of triple blockade of...
Compugen Reports Third Quarter 2021 Results PR Newswire - COM701, Opdivo® and BMS-986207, triple combination dose escalation Phase 1/2 data being presented at 36 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) clears the path to studies in se...
Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021 - COM902, high affinity, IgG4, reduced Fc effector function, anti-TIGIT antibody was well tolerated with a favorable safety profile ...
Ambitious Israel-based biotech Compugen 's (NASDAQ: CGEN) stock had one of the best days in its history Thursday. The shares rose 14% after the company revealed that a deep-pocketed strategic investor will top its list of institutional stockholders. Compugen said that it has str...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...